Global collaborative clinical development of GA101
A clinical development program for GA101 involving a global Phase 3 trial conducted jointly with Chugai Pharmaceutical and the pursuit of expanded indications, including idiopathic nephrotic syndrome.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.